Kintor Pharma sets Hong Kong IPO in motion
China-based Kintor Pharmaceutical has kicked off bookbuilding for its Hong Kong listing, the latest in a stream of healthcare IPOs in the city. The issuer is targeting HK$1.86bn ($240.1m) in proceeds.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: